v3.25.0.1
Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2023
Dec. 31, 2022
Revenue:            
Total revenue $ 2,257 $ 2,217 $ 6,833 $ 7,024 $ 9,154 $ 8,184
Cost of revenue:            
Total cost of revenue 902 910 2,843 2,981 3,892 3,861
Gross profit 1,355 1,307 3,990 4,043 5,262 4,323
Operating expenses:            
Research and development 908 998 2,766 2,958 4,035 5,917
Sales and marketing 2,143 1,702 6,169 6,069 7,812 14,915
General and administrative 2,048 2,723 7,902 9,733 12,267 14,629
Total operating expenses 5,099 5,423 16,837 18,760 24,114 35,461
Loss from operations (3,744) (4,116) (12,847) (14,717) (18,852) (31,138)
Other income (expense), net:            
Change in fair value of warrant liabilities 174 (1,201) 1,314 (233) 629 1,704
Interest (expense) income, net (5) 12 (20) 46 48 17
Forgiveness of DECD loan 1,000 1,000
Other expense, net 28 599 (153) 303 485 (468)
Total other income (expense), net 197 (590) 1,141 1,116 2,162 1,253
Net loss $ (3,547) $ (4,706) $ (11,706) $ (13,601) $ (16,690) $ (29,885)
Net loss per share - basic $ (0.23) $ (0.48) $ (0.88) $ (1.54) $ (1.81) $ (3.85)
Net loss per share - diluted $ (0.23) $ (0.48) $ (0.88) $ (1.54) $ (1.81) $ (3.85)
Basic weighted average common shares used to compute net loss per common share 15,405,672 9,776,436 13,269,646 8,838,342 9,233,306 7,769,109
Diluted weighted average common shares used to compute net loss per common share 15,405,672 9,776,436 13,269,646 8,838,342 9,233,306 7,769,109
Product [Member]            
Revenue:            
Total revenue $ 2,257 $ 2,217 $ 6,833 $ 7,023 $ 9,153 $ 7,970
Cost of revenue:            
Total cost of revenue 902 910 2,843 2,981 3,892 3,694
Genetics [Member]            
Revenue:            
Total revenue $ 1 1 214
Cost of revenue:            
Total cost of revenue         $ 167